Literature DB >> 23949581

In vitro immunization of Epstein-Barr virus-immortalized B cells augments antigen-specific antibody production.

Gakuro Harada1, Shin-Ei Matsumoto, Makiko Yamashita, Kaoru Fujii, Sanetaka Shirahata, Yoshinori Katakura.   

Abstract

The current method for in vitro immunization (IVI) uses several antigens including toxins, food allergens, pathogenic bacteria, and self-antigen-derived peptides that induce an antigen-specific immune response in peripheral blood mononuclear cells (PBMCs). This protocol, however, requires donor blood collection and preparation of PBMCs before every IVI. In the present study, we aimed to design a more efficient system utilizing B cells immortalized with Epstein-Barr virus (EBV-B) as host cells for IVI to make antigen-specific antibodies. Results showed that previously antigen-sensitized, EBV-B cells exposed to the antigen along with IL-6, CpG oligonucleotides, and CD40 ligand signal produced antigen-specific antibodies. These results provide evidence for a novel and easy method to expand memory-type B cells and produce antigen-specific antibodies.

Entities:  

Year:  2013        PMID: 23949581      PMCID: PMC3853636          DOI: 10.1007/s10616-013-9596-9

Source DB:  PubMed          Journal:  Cytotechnology        ISSN: 0920-9069            Impact factor:   2.058


  10 in total

1.  Generation of a human anti-tumor necrosis factor-α monoclonal antibody by in vitro immunization with a multiple antigen peptide.

Authors:  Tsukasa Fujiki; Atsuji Tsuji; Shin-ei Matsumoto; Makiko Yamashita; Kiichiro Teruya; Sanetaka Shirahata; Yoshinori Katakura
Journal:  Biosci Biotechnol Biochem       Date:  2010-09-07       Impact factor: 2.043

2.  Humanized antibodies for therapy.

Authors:  M S Co; C Queen
Journal:  Nature       Date:  1991-06-06       Impact factor: 49.962

Review 3.  Immunotherapy of Alzheimer's disease (AD): from murine models to anti-amyloid beta (Abeta) human monoclonal antibodies.

Authors:  Valeria Geylis; Michael Steinitz
Journal:  Autoimmun Rev       Date:  2005-08-01       Impact factor: 9.754

4.  Human peripheral blood cells differentially recognize and respond to two distinct CPG motifs.

Authors:  D Verthelyi; K J Ishii; M Gursel; F Takeshita; D M Klinman
Journal:  J Immunol       Date:  2001-02-15       Impact factor: 5.422

5.  A simple method for enriching populations of transfected CHO cells for cells of higher specific productivity.

Authors:  S C G Brezinsky; G G Chiang; A Szilvasi; S Mohan; R I Shapiro; A MacLean; W Sisk; G Thill
Journal:  J Immunol Methods       Date:  2003-06-01       Impact factor: 2.303

6.  Anti-peptide antibody production elicited by in vitro immunization of human peripheral blood mononuclear cells.

Authors:  Takashi Tamura; Kosuke Tomimatsu; Yoshinori Katakura; Makiko Yamashita; Shin-ei Matsumoto; Yoshihiro Aiba; Yeon Suk Jung; Yoshiichi Abe; Tsukasa Fujiki; Kiichiro Teruya; Sanetaka Shirahata
Journal:  Biosci Biotechnol Biochem       Date:  2007-12-07       Impact factor: 2.043

7.  In vitro immunization of human peripheral blood lymphocytes: establishment of B cell lines secreting IgM specific for cholera toxin B subunit from lymphocytes stimulated with IL-2 and IL-4.

Authors:  A Ichikawa; Y Katakura; K Teruya; S Hashizume; S Shirahata
Journal:  Cytotechnology       Date:  1999-09       Impact factor: 2.058

8.  Epitope analysis of human monoclonal antibody specific for rice allergenic protein generated by in vitro immunization.

Authors:  S Y Shim; Y Katakura; A Ichikawa; K Teruya; T Matsuda; S Shirahata
Journal:  Cytotechnology       Date:  2001-07       Impact factor: 2.058

9.  Productivity enhancement of recombinant protein in CHO cells via specific promoter activation by oncogenes.

Authors:  Y Katakura; P Seto; T Miura; H Ohashi; K Teruya; S Shirahata
Journal:  Cytotechnology       Date:  1999-09       Impact factor: 2.058

10.  CD40-CD40 ligand interactions are critical in T-B cooperation but not for other anti-viral CD4+ T cell functions.

Authors:  A Oxenius; K A Campbell; C R Maliszewski; T Kishimoto; H Kikutani; H Hengartner; R M Zinkernagel; M F Bachmann
Journal:  J Exp Med       Date:  1996-05-01       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.